Proton therapy and concurrent chemotherapy may reduce bone marrow toxicity in advanced lung cancer

Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news145808497.html">Proton therapy and concurrent chemotherapy may reduce bone marrow toxicity in advanced lung cancer</a></p> <p>Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.</p>